• Profile
Close

Early results of lower dose dasatinib (50 mg daily) as frontline therapy for newly diagnosed chronic-phase chronic myeloid leukemia

Cancer May 14, 2018

Naqvi K, et al. - Researchers evaluated the efficacy and safety of a lower dose of dasatinib (50 mg daily), a BCR-ABL1 and Src family tyrosine kinase inhibitor, in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP), since myelosuppression and pleural effusions are associated with the approved 100 mg daily oral dose. At 3 months, the observed rates of patients achieving BCR-ABL1 transcript levels ≤ 10% and ≤ 1% by the International Standard were 93% and 72%, respectively. At 12 months, a major molecular response, a molecular response with a 4.0-log reduction, and a molecular response with a 4.5-log reduction, respectively, was achieved by 79%, 71%, and 46% of the patients. Overall, dasatinib 50 mg daily showed activity as well as good tolerability in patients with newly diagnosed CML-CP.

Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay